Institutional shares held 25.6 Million
195K calls
133K puts
Total value of holdings $397M
$3.01M calls
$2.05M puts
Market Cap $439M
26,576,400 Shares Out.
Institutional ownership 96.49%
# of Institutions 179


Latest Institutional Activity in ARCT

Top Purchases

Q3 2024
Nikko Asset Management Americas, Inc. Shares Held: 2.32M ($38.2M)
Q3 2024
Sumitomo Mitsui Trust Holdings, Inc. Shares Held: 2.28M ($37.6M)
Q3 2024
Bio Impact Capital LLC Shares Held: 220K ($3.62M)
Q3 2024
Vanguard Group Inc Shares Held: 1.58M ($26M)
Q3 2024
Empire Life Investments Inc. Shares Held: 151K ($2.49M)

Top Sells

Q3 2024
Morgan Stanley Shares Held: 267K ($4.41M)
Q3 2024
Portolan Capital Management, LLC Shares Held: 129K ($2.13M)
Q3 2024
Millennium Management LLC Shares Held: 236K ($3.9M)
Q3 2024
Wellington Management Group LLP Shares Held: 96.3K ($1.59M)
Q3 2024
Granahan Investment Management, LLC Shares Held: 86.4K ($1.43M)

About ARCT

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.


Insider Transactions at ARCT

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
18.8K Shares
From 6 Insiders
Exercise of conversion of derivative security 18.8K shares
Sell / Disposition
114K Shares
From 2 Insiders
Open market or private sale 114K shares

Track Institutional and Insider Activities on ARCT

Follow Arcturus Therapeutics Holdings Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARCT shares.

Notify only if

Insider Trading

Get notified when an Arcturus Therapeutics Holdings Inc. insider buys or sells ARCT shares.

Notify only if

News

Receive news related to Arcturus Therapeutics Holdings Inc.

Track Activities on ARCT